RE:Nobody likes delays...The real question that everyone from the board to shareholders needs to be asking is- why can't this group enroll patients into the Tigris trial?
4 patients a month is only half of their "worst case" scenario! And that's the best we've seen.
If you do the math on 102 patients divided by 4 per month- you will freak out at the length of this trial at this rate.
The Covid excuse has been gone since spring, and each month they prove they are unable to get the numbers up.
I understand you are looking for a silver lining, but there is clearly a basic, first principle problem with Management's aprroch to this trial.
Debra Foster is still listed on Spectral's site as VP of Clinical Development when we know she is long retired and living somewhere sunny.
How much longer can the board simply shrug their shoulders at these horrible numbers- while 1 million bucks disappears each month?
The perfomance warrants/ carrot have not worked time to try the stick.